The Merck Accelerator Program 2019
The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites events in Africa, startups can find their perfect fit and connect to the global network for collaboration. Are you ready to partner with Merck? (Source: World Pharma News)
Source: World Pharma News - September 20, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Discovery could explain failed clinical trials for Alzheimer's, and provide a solution
Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trials have failed. The study also identifies a clinically approved drug which breaks the vicious cycle and protects against memory-loss in animal models of Alzheimer's. (Source: World Pharma News)
Source: World Pharma News - September 19, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novo Nordisk announces plans to transform its approach to Research & Development
Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases. To enable increased investment in transformational biological and technological innovation within both core and new therapy areas, approximately 400 employees will be laid off from R&D roles in Denmark and China. (Source: World Pharma News)
Source: World Pharma News - September 19, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Aspirin found not to prolong healthy aging
Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial published online Sept. 16 in three papers in the New England Journal of Medicine. The large clinical trial, which began in 2010, aimed to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous (Source: World Pharma News)
Source: World Pharma News - September 18, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest global survey to date investigating perceptions of Alzheimer's disease. Findings show that most adults (62 percent) are worried (Source: World Pharma News)
Source: World Pharma News - September 18, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Clinical gene discovery program solves 30 medical mysteries
A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has plagued one or more family members. The Brigham Genomic Medicine (BGM) program, an integrated, multi-disciplinary clinical and research program, brings together world-class experts from across (Source: World Pharma News)
Source: World Pharma News - September 17, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate), Symbicort Turbuhaler (budesonide/formoterol fumarate) and PT009 (budesonide/formoterol fumarate) in patients with (Source: World Pharma News)
Source: World Pharma News - September 17, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Dietary fiber reduces brain inflammation during aging
As mammals age, immune cells in the brain known as microglia become chronically inflamed. In this state, they produce chemicals known to impair cognitive and motor function. That’s one explanation for why memory fades and other brain functions decline during old age. But, according to a new study from the University of Illinois, there may be a remedy to delay the inevitable: dietary fiber. (Source: World Pharma News)
Source: World Pharma News - September 14, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Abbott is named global industry leader in sustainability for the sixth consecutive year on the Dow Jones Sustainability Index (DJSI)
For the sixth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries. (Source: World Pharma News)
Source: World Pharma News - September 13, 2018 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

FDA approves new kind of treatment for hairy cell leukemia
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL. (Source: World Pharma News)
Source: World Pharma News - September 13, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Drug for pancreatic cancer developed by college of pharmacy researchers
A treatment for highly aggressive and commonly fatal pancreatic cancer is being developed, reports a University of Houston researcher who has designed a new medicine that can inhibit two of the major pathways of the deadly disease. Ruiwen Zhang, M.D., Ph.D. and Robert L. Boblitt Endowed Professor in Drug Discovery, has published his findings, along with research associate professor of pharmacology Wei Wang, M.D., Ph.D., in Cancer Research Journal. (Source: World Pharma News)
Source: World Pharma News - September 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Regrowing dental tissue with stem cells from baby teeth
Sometimes kids trip and fall, and their teeth take the hit. Nearly half of children suffer some injury to a tooth during childhood. When that trauma affects an immature permanent tooth, it can hinder blood supply and root development, resulting in what is essentially a "dead" tooth. Until now, the standard of care has entailed a procedure called apexification that encourages further root development, but (Source: World Pharma News)
Source: World Pharma News - September 11, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
Alcon, the global leader in eye care and a division of Novartis, today announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of its proposed spinoff from Novartis. Alcon's new global headquarters in Geneva will be the primary location for Alcon's senior corporate leadership and other corporate and commercial functions. (Source: World Pharma News)
Source: World Pharma News - September 11, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Study links widely-used drug azathioprine to skin cancers
A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important contributor to skin cancer development, in a research study carried out at the University of Dundee, Queen Mary University of London and the Wellcome Sanger Institute. (Source: World Pharma News)
Source: World Pharma News - September 10, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Tezepelumab granted Breakthrough Therapy Designation by US FDA
AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers. (Source: World Pharma News)
Source: World Pharma News - September 7, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. (Source: World Pharma News)
Source: World Pharma News - September 6, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Social Media in the Pharmaceutical Industry Conference 2019
21 - 23 January 2019, London, UK. SMi Group are delighted to present the return of their 11th annual Social Media in the Pharmaceutical Industry conference to London on the 21st - 23rd January 2019. Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. (Source: World Pharma News)
Source: World Pharma News - September 5, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy
Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004). (Source: World Pharma News)
Source: World Pharma News - September 5, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Antioxidant reduces risk for second heart attack, stroke
Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the American College of Cardiology explains what happens inside blood vessels to increase risk - and suggests a new way to treat it. (Source: World Pharma News)
Source: World Pharma News - September 4, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New tablet production facility in Ingelheim: Centerpiece for global launches
Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches. (Source: World Pharma News)
Source: World Pharma News - September 3, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Shire completes sale of oncology franchise
Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the global rights to ONCASPAR® and ex-US and ex-Taiwan rights to ONIVYDE®, as well as Oncology pipeline assets. David Lee, who was previously the head of Shire's Global Genetic Diseases and Oncology franchises, will continue with Servier as CEO of its new US commercial subsidiary, Servier Pharmaceuticals. (Source: World Pharma News)
Source: World Pharma News - August 31, 2018 Category: Pharmaceuticals Tags: Featured Shire Business and Industry Source Type: news

Bayer accelerates six new startups
Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies from Canada, Germany, Israel, Spain, the United Kingdom and the United States came out ahead of more than 1,800 competitors from 100 countries. They now have 100 days in which to intensively drive the further development of their products and solutions with expertise and investment from Bayer. (Source: World Pharma News)
Source: World Pharma News - August 30, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Cannabis extract helps reset brain function in psychosis
Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psychosis. Results from a new MRC-funded trial, published in JAMA Psychiatry, provide the first evidence of how cannabidiol acts in the brain to reduce psychotic symptoms. (Source: World Pharma News)
Source: World Pharma News - August 29, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and Astellas amend clinical research protocols for two phase 3 trials of enzalutamide in patients with hormone-sensitive prostate cancer
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC). These amendments accelerate timelines for the anticipated primary completion dates of both trials. (Source: World Pharma News)
Source: World Pharma News - August 29, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

New cancer treatment uses enzymes to boost immune system and fight back
Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill cancer cells but instead empowers the immune system to eradicate unwanted cells on its own. PEG-KYNase is designed to degrade kynurenine, a metabolite produced by numerous tumors that suppresses the immune system. (Source: World Pharma News)
Source: World Pharma News - August 28, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah ® (tisagenlecleucel)
Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. (Source: World Pharma News)
Source: World Pharma News - August 27, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

For first time in 40 years, cure for acute leukemia within reach
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now. As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia. (Source: World Pharma News)
Source: World Pharma News - August 24, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS). SOLAR-1 is evaluating BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and men with hormone-receptor positive, (Source: World Pharma News)
Source: World Pharma News - August 23, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - August 22, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Consuming milk at breakfast lowers blood glucose throughout the day
A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas Goff, PhD, and the team of scientists from the Human Nutraceutical Research Unit at the University of Guelph, in collaboration with the University of Toronto, examined the effects of consuming high-protein milk at breakfast on blood glucose levels and satiety after breakfast and after a second meal. (Source: World Pharma News)
Source: World Pharma News - August 21, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS ™ real-world data program grows to sample size of nearly one million lives worldwide
The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the posters to be presented are new analyses from the global real-world data (RWD) program, ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies), exploring the effectiveness and safety of anticoagulants, including Eliquis, among patients with non-valvular atrial fibrillation. (Source: World Pharma News)
Source: World Pharma News - August 20, 2018 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins
Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications. (Source: World Pharma News)
Source: World Pharma News - August 17, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

New approach to fight tuberculosis, a leading cause of death worldwide
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost 100 years ago, offers limited protection and patients are becoming increasingly resistant to available drugs. (Source: World Pharma News)
Source: World Pharma News - August 16, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck awarded Australian CRISPR nickase patent for foundational genome-editing technology
Merck, the vibrant science and technology company, today announced that the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases. Paired nickases represent a significant step in increasing safety by driving specificity through a highly flexible and efficient approach to reduce off-target effects. (Source: World Pharma News)
Source: World Pharma News - August 15, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Researchers artificially generate immune cells integral to creating cancer vaccines
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports. The researchers discovered a way to grow the immune cells, called dendritic cells, at large scale in the lab to study them for their potential use in highly refined cancer vaccines to prevent patients' cancer from coming back. (Source: World Pharma News)
Source: World Pharma News - August 14, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

The medicine of the future against infection and inflammation?
Researchers at Lund University in Sweden, have in collaboration with colleagues in Copenhagen and Singapore, mapped how the body's own peptides act to reduce infection and inflammation by deactivating the toxic substances formed in the process. The study is published in Nature Communications and the researchers believe their discovery could lead to new drugs against infection and inflammation, for example in wound healing. (Source: World Pharma News)
Source: World Pharma News - August 13, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs. (Source: World Pharma News)
Source: World Pharma News - August 10, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Selumetinib granted orphan designation in Europe for neurofibromatosis type 1
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). (Source: World Pharma News)
Source: World Pharma News - August 9, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Compounds in 'monster' radish could help tame cardiovascular disease
Step aside carrots, onions and broccoli. The newest heart-healthy vegetable could be a gigantic, record-setting radish. In a study appearing in ACS' Journal of Agricultural and Food Chemistry, scientists report that compounds found in the Sakurajima Daikon, or "monster," radish could help protect coronary blood vessels and potentially prevent heart disease and stroke. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC) - consisting of Imperial College London and the Universities of Oxford and Edinburgh - Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). (Source: World Pharma News)
Source: World Pharma News - August 7, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Taking a pill can effectively treat brutal lung disease
Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking cholesterol-busting pills called statins can effectively treat the disease. That's good news for people with PAP because at present the current standard treatment is something called a whole lung lavage. (Source: World Pharma News)
Source: World Pharma News - August 7, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Differences in immune responses due to age, sex, and genetics
Over the course of our life, we are continuously exposed to pathogens such as viruses and bacteria, meaning that our immune system is constantly at work. When stimulated by either pathogen or vaccine, the immune system notably mounts what is known as a "humoral response", which corresponds to the production of antibodies that can help fight infections and provide long-term protection. (Source: World Pharma News)
Source: World Pharma News - August 6, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million
Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim of the program is to give selected change-makers around the world new opportunities to grow and transform great ideas into powerful impact solutions that help to improve the lives of millions. (Source: World Pharma News)
Source: World Pharma News - August 6, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Mushrooms of the Far East hold promise for the anti-cancer therapy
Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities and low-toxicity. These compounds may offer new avenues for oncology, providing us with either stand-alone alternatives to chemotherapy, chemopreventive medicines, or drugs to be used in combination with other therapies. (Source: World Pharma News)
Source: World Pharma News - August 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island
Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets. (Source: World Pharma News)
Source: World Pharma News - August 2, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Innovative technique converts white fat to brown fat
Brown fat tissue in the body can burn enormous amounts of energy to generate heat, and studies in humans and animals have suggested that increasing the amount of healthy brown fat might help weight management and reduce symptoms of diabetes. However, how to safely and effectively increase brown fat has been a significant challenge for researchers. (Source: World Pharma News)
Source: World Pharma News - August 1, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis marks a new era for migraine patients with the EU approval of Aimovig ®, a first-of-its-kind treatment specifically designed for migraine prevention
Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. (Source: World Pharma News)
Source: World Pharma News - July 30, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Researchers design a nano-carrier to release drugs into damaged cells
Senescent cells are damaged cells that do not perform their normal roles anymore but that are not dead -hence they are commonly known as zombi cells. These cells interfere with the functioning of the tissue in which they accumulate. Senescence is a cell program that is triggered by many types of damage and senescent cells are present in many diseases. (Source: World Pharma News)
Source: World Pharma News - July 27, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news